NeuraMetrix, Inc. **detects and measures** brain disorders and injuries with **non-invasive** software that measures **sub-clinical** human cognitive and motor function based on **typing cadence**

**Mission**
To provide quantitative measurement tools which are the standard for early detection, measurement, and monitoring of brain health

**Goal**
To be the leading independent brain health monitoring company by building the world's most innovative and effective brain health monitoring platform

**Overview**
Disruptive technology to detect/monitor progression of brain disorders
- Initial study with MJFF Fox Trial Finders completed on Parkinson’s Disease
- Vast implications for patients, neurologists and big pharma/biotech

Remote, real-time, continuous monitoring
- Improved disease management by neurologists
- Objective data regarding treatment changes
- Seamlessly connects neurologists and patients via “dashboards”

Online, highly-scalable, cost-effective non-invasive solution
- Patients measured during “natural typing behavior”
- Independent of language, culture or education
- Does not require tests, sensors, gross motor skills or physician interaction
- Fully integrated online technology platform – software solution
- Results are automatically measured, analyzed and reported

Early detection/measurement enable development of new therapies

**Scientific Advisory Board**
Robert W. Mahley, MD, PhD, Chairman (Gladstone Institutes)
Carrolee Barlow, MD, PhD (Parkinson’s Institute and Clinical Center)
Wolfgang H. Oertel, MD (Philipps-Universität Marburg)
Bruce L. Miller, MD (UCSF)

**Active Research**

**Disease/Disorder**
- Parkinson’s Disease
- Alzheimer’s
- ADHD
- Depression
- Huntington’s Disease
- REM Sleep Behavior Disorder
- Wolfram Syndrome

**Research Affiliates**
- Karolinska Institutet, Stockholm (Sweden)
- Parkinson’s Institute and Clinical Center (US)
- Philipps-Universität Marburg (Germany)
- Sogn og Fjordane University College (Norway)
- Stanford University (US)
- University of St Andrews (Scotland)
- University of Toronto (Canada)
- University of Ulm (Germany)
- University of Iowa (US)
- Washington University, St Louis (US)

**Applications**
Patient monitoring/med management
Drug development/clinical trials
Early detection/diagnostics

**Contact**
Jan Samzelius, CEO (jan.samzelius@neurametrix.com, 415-420-6636)
Bill Wisialowski, COO (wiz@neurametrix.com, 650-773-1441)

www.neurametrix.com